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Abstract
Hyosun Kim’s report “Trouble Spots in Online Direct to Consumer Prescription Drug Promotion: A content 
Analysis of FDA Warning Letters” aims to teach marketers how to avoid breaching current Food and Drug 
Administration (FDA) guidelines in their online drug promotion. While Kim hopes to minimise the potential 
for online promotion to misinform consumers and the study is carefully conducted, teaching drug marketers 
how to avoid the common mistakes in online drug promotion is more likely to make marketers more adept at 
spinning information than appropriately balancing it.
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Direct-to-consumer advertising (DTCA) of prescription pharmaceuticals, whether the medium is print, broadcast or online, is a vexed issue. 
Discussion of the pros and cons of prescription drug DTCA 
is always morally charged with valid claims and equally valid 
counter-claims, plausible allegations and cogent rebuttals, 
heroic narratives of consumer empowerment and atrocity 
stories of therapeutic disasters. If we pose the bald question 
“is DTCA helpful” the best one can answer on the available 
evidence is a frustrating: ‘yes and no, maybe, it depends.’ 
Understandably, many policy-makers will conclude that 
any ‘truth’ to be found on the question of whether DTCA is 
‘therapeutic or toxic?’1 is hopelessly relative to an individual’s 
ideological commitments. It would be hoping for too much 
to expect that Hyosun Kim’s report “Trouble Spots in Online 
Direct to Consumer Prescription Drug Promotion: A content 
Analysis of FDA Warning Letters”2 could do anything close to 
resolving the tricky substantive issues it raises. However, to be 
fair, it does reinforce the notion that without restraint online 
prescription drug promotion may be as problematic as it is 
productive.
Kim’s research report enters this murky fray to offer drug 
marketers a way to optimise the likelihood of their online 
advertising being helpful, or at least not misleading. There 
is much to commend it. It is a sound piece of descriptive 
qualitative research and the author should be applauded for 
seeking to improve the quality online DTCA (or e-DTCA) 
and for undertaking a rigorous study to do so. Kim identifies 
a pressing issue for those concerned with quality (ie, 
appropriate, timely, and safe) use of prescription medicines 
– the quality of medicine information rebounding through 
the online environment ie, the internet and social media. 
Unquestionably, the ubiquity of the internet and more 
recently social media have changed the way people seek and 
receive health information and pharmaceutical marketers 
have been quick to exploit this potential. The rapidity of this 
change has given rise to concerns that policy and regulation 
have not kept pace and that controls applied to DTCA in 
traditional media are not adequate for the very different 
communicative environment and ‘participatory culture’ of 
the internet and social media. Food and Drug Administration 
(FDA) guidelines have been developed but are somewhat ad 
hoc.
Unsurprising then that marketers and regulators may find 
themselves’ occasionally at odds over certain elements of 
online drug campaigns. Kim sees a way to address this – teach 
marketers how to avoid breaching current FDA guidelines in 
a way that prompts the FDA to issue a ‘notice of violation’ 
(NOV) warning letter. The aim is ‘diagnostic,’ to qualitatively 
study such letters and identify how a particular advertising 
campaign or part thereof has breached FDA guidelines and 
thereby provide drug marketers with the ‘context’ to the FDA’s 
issuing a NOV.
Kim’s study asks a set of straightforward descriptive research 
questions: What types of online promotional received the 
most letters? What drug categories that have received letters? 
What types of  legal violations does the FDA allege? Do alleged 
violations differ by online promotion type? The methods used 
to answer these questions are also relatively straightforward, 
appropriate and carefully conducted. The letters have been 
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subject to a content analysis ie, they have been read, coded and 
organised into descriptive categories relevant to each research 
question. The analysis showed that: the majority of violations 
were related to advertisements on branded drug websites, 
online paid advertisements and online video promotion; 
the promotion of drugs for chronic diseases attracted most 
warning letters; inadequate risk and efficacy information 
were the most frequently cited violations; and online 
advertisements were the type of promotion most frequently 
subject to a warning letter. Kim’s most significant finding 
is that online prescription drug advertising, like DTCA in 
broadcast media, fails to present risk and benefit information 
in a balanced manner. The main recommendation of the 
paper is for the FDA to provide “comprehensive guidelines 
that address the accessibility and visibility of information 
would help pharmaceutical marketers avoid putting so many 
misleading promotional activities online.”
It is clear that Kim accepts the proposition that online 
DTCA, properly guided and responsibly executed, is a force 
for good. Before I challenge this proposition, I declare that I 
have a track record in opposing DTCA in my home country 
of Australia having researched and published on the issue 
(eg, Hogue et al,3 Doran and Lofgren4). My partisanship on 
this issue, however, does not extend to denying that there are 
considerable challenges in making a morally or empirically 
watertight case against DTCA. Both advocates and opponents 
of DTCA may, respectively, muster an inventory of benefits 
for or litany of complaints against DTCA and offer theoretical 
and empirical support for its benefits and drawbacks. To 
be fair, both sides can offer cogent arguments. The claims 
and counterclaims are well-rehearsed in the literature and 
readers may refer to the following references for more 
detailed descriptions of the opposing arguments.5-9 Briefly 
the purported benefits include, redressing under-diagnosis 
and under-treatment of conditions such as diabetes and 
depression, improving patient compliance with treatment, 
improving patient education and improving patient-doctor 
interaction. The purported harms include, misinforming 
patients, inappropriate prescribing, prompting rapid uptake 
of unproven medicines and increasing drug expenditure.
There is not the space here to trenchantly pull apart the 
opposing positions and the evidence that is mobilised in 
support of their arguments. In this commentary, I will 
offer a counterpoint to Kim’s main argument that with 
better understanding of ‘context’ and stronger guidelines 
drug marketer’s will able and willing to avoid presenting 
information in a misleading way, and thereby help consumers 
have better discussions with their doctor and make better 
treatment decisions. 
The context Kim refers to is essentially the detail of the 
FDA’s judgement that the product information presented 
within online drug promotion does not adequately balance 
risks and benefits. The solution it appears is to institute 
more comprehensive guidelines that will help marketers 
strike a balance – give equal space and draw equal attention 
to information on risks as well as benefits. While an 
understanding of context, as defined by Kim, may prompt 
marketers to give greater attention to the balance of the 
drug information it is far from obvious that marketers will 
forego framing their communication in a way that persuades 
consumers that the benefits are likely and the risks remote. 
This proposal seriously underplays drug marketers’ 
main motivation. The provision of information about 
pharmaceutical products by marketers is from the very start 
a fraught exercise by virtue of the incontrovertible fact that 
drug marketing is predicated on persuasion to maximise 
sales and return to shareholders. Balancing benefit-risk 
information is always subordinate to these imperatives. As 
I have argued elsewhere if maximising sales is a perfectly 
legitimate objective, it is also indiscriminate – with the 
capacity to consume as important as the capacity to benefit.
Secondly, it is difficult in the extreme to imagine guidelines 
that can adequately counter drug marketers’ essential urge 
to ‘spin’ product information to emphasise the potential 
benefits and underplay the potential risks or uncertain 
efficacy. As McKenzie et al10 have pointed out, there are no 
simple evaluative principles available by which the quality of 
drug product information may be objectively judged. Drug 
information may be factually accurate but its presentation 
involves the use of evocative imagery and language that 
(subtly or otherwise) convey narratives and themes that 
move beyond facts to appeal to universals such as the dread 
of sickness and desire to be better. Compelling marketers to 
ensure information is balanced visible and accessible does not 
address these more potent elements of advertising.
Kim asserts that “DTCA helps consumers have better 
discussions with their physicians and to make better health-
related decisions as active consumers.” Here we can see the 
now familiar trope of the empowered consumer that has 
been mobilised by pharmaceutical companies since they first 
commenced targeting the public with DTCA in the 1990s. But 
if it is plausible that e-DTCA gives consumers the information 
they need to actively engage with their doctors in treatment 
decisions, it is equally plausible that this engagement will 
follow a ‘script’ that favours the branded drug. 
Mogull and Balzhiser’s11 rhetorical analysis of web-based 
DTCA for prescription drugs to treat migraine shows how the 
doctor-patient dialogue can be shaped toward diagnosis and 
the issuing of a prescription. The online promotional materials 
employed imagery and text that emphasise the capacity of the 
consumer to take control of their illness, primarily by talking 
to their doctor about the branded drug. The promotional 
materials analysed by Mogull and Balzhiser do more than 
merely prompt the reader to ‘ask your doctor,’ they also 
provide a set of questions that the consumer may use to guide 
the discussion ie, the consumer arrives at their doctors office 
with a prepared script. Under such circumstances, the most 
influential presence in the ensuing discussion is neither the 
doctor nor the patient but the pharmaceutical company. The 
provision of information here is less about empowerment and 
more about direction.
Although laudable, Kim’s aim of teaching drug marketers 
how to avoid the common mistakes in online drug promotion 
is more likely to make marketers more adept at spinning 
information than appropriately balancing it. Nevertheless, 
given that DTCA is legally permissible in the United 
States and it is unlikely that this will be reversed, Kim’s 
recommendation for more comprehensive guidelines for 
online prescription drug promotion needs to be heeded. The 
increasing pervasiveness of digital communication will mean 
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drug marketers will continue to adopt innovative e-DTCA 
tactics12 and guidelines must be flexible enough to keep 
abreast of and adequately account for developments in online 
drug promotion. For this to be achieved, more will need to 
be known about how pharmaceutical companies are adapting 
DTCA to the online environment. As Mackey and Liang12 
have noted, here lies the most urgent challenge in ensuring 
that DTCA is more productive than problematic, compelling 
pharmaceutical companies to be more transparent about what 
they are doing and spending when ‘informing’ consumers. 
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